ALNY 株価推移チャート
ALNY 財務
Alnylam Pharmaceuticals Inc
$301.11
1.06%
$3.18
終値： May 05, 16:00:00 GMT-4
$300.89
-0.07%
$-0.22
アフターマーケット：May 05, 20:00:00 GMT-4
戻る
Alnylam Pharmaceuticals Inc (ALNY) 財務
主要データ
前終値
$297.92
始値
$297.81
当日レンジ
$295.02 - $302.67
52週レンジ
$214.76 - $495.55
取引高
602.0K
平均取引高
1.4M
配当利回り
--
1株当たり利益(TTM)
2.25
時価総額
$39.9B
ALNYとは何ですか？
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
